Phase 2 trial of Intravenously Administered Plerixafor for Stem Cell Mobilization in Patients with Multiple Myeloma Following Lenalidomide Based Initial Therapy

Initial therapy of multiple myeloma with lenalidomide-based regimens can compromise stem cell collection, which can be overcome with the addition of plerixafor. Plerixafor is typically given subcutaneously (SQ), with collection approximately 11 hours later for maximum yield. Intravenous (IV) adminis...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Kumar, Shaji K., Mikhael, Joseph, LaPlant, Betsy, Lacy, Martha Q., Buadi, Francis K., Dingli, David, Gertz, Morie A., Laumann, Kristina, Miceli, Teresa, Mahlman, Marcia, Bergsagel, Leif P., Hayman, Suzanne R., Reeder, Craig, Stewart, A. Keith, Dispenzieri, Angela, Gastineau, Dennis A., Winters, Jeffrey L
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2013
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3946357/
https://ncbi.nlm.nih.gov/pubmed/24185588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2013.175
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia